Literature DB >> 28176275

Reduced Activated T Lymphocytes (CD4+CD25+) and Plasma Levels of Cytokines in Parkinson's Disease.

Natalia Pessoa Rocha1,2,3, Frankcinéia Assis4, Paula Luciana Scalzo5, Érica Leandro Marciano Vieira6, Izabela Guimarães Barbosa6, Mariana Soares de Souza7, Paulo Pereira Christo7, Helton José Reis8, Antonio Lucio Teixeira6,9.   

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease. The cause of neurodegeneration in PD is not completely understood, and evidence has shown that inflammatory/immune changes may be involved in PD pathophysiology. Herein, we aimed to determine the profile of the peripheral immune system in patients with PD in comparison with controls. Forty patients with PD and 25 age- and gender-matched controls were enrolled in this study. From these, 23 PD patients and 21 controls were included in the immunophenotyping analyses. Peripheral blood was drawn on the same day of the clinical assessment and submitted to plasma separation for enzyme-linked immunosorbent assay or cytometric bead array. Immunophenotyping analyses of the peripheral blood were performed by flow cytometry. We found that patients with PD presented peripheral immune changes evidenced by decreased percentage of T lymphocytes (CD3+ cells), especially activated T lymphocytes (CD4+CD25+ cells), when compared with controls. In line with these results, we also found decreased plasma levels of the cytokines IL-4, IL-6, IL-10, TNF, IFN-γ, and IL-17A in the PD group. In vitro experiments demonstrated that the production of cytokines by peripheral blood mononuclear cells harvested from healthy young donors was reduced after exposure to the anti-parkinsonian drugs levodopa and pramipexole. Our data corroborate the hypothesis that immunological mechanisms are involved in PD. It is not clear whether the differences that we have found are due to adaptive mechanisms or to changes associated with PD, including pharmacological treatment, or even directly related to the disease pathophysiology. Future studies are needed in this regard.

Entities:  

Keywords:  Cytokines; Immune system; Immunophenotyping; Inflammation; Leukocytes; Parkinson’s disease

Mesh:

Substances:

Year:  2017        PMID: 28176275     DOI: 10.1007/s12035-017-0404-y

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  24 in total

1.  Alterations of T-lymphocyte populations in Parkinson disease.

Authors:  Yasuhiko Baba; Ataru Kuroiwa; Ryan J Uitti; Zbigniew K Wszolek; Tatsuo Yamada
Journal:  Parkinsonism Relat Disord       Date:  2005-09-09       Impact factor: 4.891

2.  Impaired cytokine production by peripheral blood mononuclear cells and monocytes/macrophages in Parkinson's disease.

Authors:  Y Hasegawa; T Inagaki; M Sawada; A Suzumura
Journal:  Acta Neurol Scand       Date:  2000-03       Impact factor: 3.209

Review 3.  Cytokine networking of innate immunity cells: a potential target of therapy.

Authors:  Ilja Striz; Eva Brabcova; Libor Kolesar; Alena Sekerkova
Journal:  Clin Sci (Lond)       Date:  2014-05       Impact factor: 6.124

4.  Dopaminergic therapies modulate the T-CELL proteome of patients with Parkinson's disease.

Authors:  Tiziana Alberio; Agnese C Pippione; Cristoforo Comi; Simone Olgiati; Daniela Cecconi; Maurizio Zibetti; Leonardo Lopiano; Mauro Fasano
Journal:  IUBMB Life       Date:  2012-07-20       Impact factor: 3.885

5.  Defective production of interleukin-2 in patients with idiopathic Parkinson's disease.

Authors:  H Klüter; P Vieregge; H Stolze; H Kirchner
Journal:  J Neurol Sci       Date:  1995-11       Impact factor: 3.181

6.  Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism.

Authors:  J Bas; M Calopa; M Mestre; D G Molleví; B Cutillas; S Ambrosio; E Buendia
Journal:  J Neuroimmunol       Date:  2001-02-01       Impact factor: 3.478

7.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

8.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

9.  The FAB: a Frontal Assessment Battery at bedside.

Authors:  B Dubois; A Slachevsky; I Litvan; B Pillon
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

10.  [Immune factors or depression? Fatigue correlates in Parkinson's disease].

Authors:  Z Katsarou; S Bostantjopoulou; O Hatzizisi; E Giza; A Soler-Cardona; G Kyriazis
Journal:  Rev Neurol       Date:  2007 Dec 16-31       Impact factor: 0.870

View more
  16 in total

Review 1.  The correlation of lymphocyte subsets, natural killer cell, and Parkinson's disease: a meta-analysis.

Authors:  Sen Jiang; Hua Gao; Qin Luo; Pengfei Wang; Xinling Yang
Journal:  Neurol Sci       Date:  2017-05-11       Impact factor: 3.307

Review 2.  Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson's Disease.

Authors:  Milan Zimmermann; Kathrin Brockmann
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 3.  T Lymphocytes in Parkinson's Disease.

Authors:  Elena Contaldi; Luca Magistrelli; Cristoforo Comi
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

4.  Abnormal subpopulations of peripheral blood lymphocytes are involved in Parkinson's disease.

Authors:  Congcong Sun; Zhenxiang Zhao; Wenfei Yu; Mingshu Mo; Chengyuan Song; Youfeng Si; Yiming Liu
Journal:  Ann Transl Med       Date:  2019-11

5.  Evidence for Peripheral Immune Activation in Parkinson's Disease.

Authors:  Xueping Chen; Weihua Feng; Ruwei Ou; Jiao Liu; Jing Yang; Jiajia Fu; Bei Cao; Yongping Chen; Qianqian Wei; Huifang Shang
Journal:  Front Aging Neurosci       Date:  2021-04-30       Impact factor: 5.750

6.  Differences of immune disorders between Alzheimer's disease and breast cancer based on transcriptional regulation.

Authors:  Wei Kong; Xiaoyang Mou; Jin Deng; Benteng Di; Ruxing Zhong; Shuaiqun Wang; Yang Yang; Weiming Zeng
Journal:  PLoS One       Date:  2017-07-18       Impact factor: 3.240

7.  Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease.

Authors:  Lori N Eidson; George T Kannarkat; Christopher J Barnum; Jianjun Chang; Jaegwon Chung; Chelsea Caspell-Garcia; Peggy Taylor; Brit Mollenhauer; Michael G Schlossmacher; Larry Ereshefsky; Mark Yen; Catherine Kopil; Mark Frasier; Kenneth Marek; Vicki S Hertzberg; Malú G Tansey
Journal:  J Neuroinflammation       Date:  2017-08-18       Impact factor: 8.322

Review 8.  Modulation of the Immune System for the Treatment of Glaucoma.

Authors:  Katharina Bell; Nadine von Thun Und Hohenstein-Blaul; Julia Teister; Franz Grus
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

Review 9.  Alpha synuclein in hematopoiesis and immunity.

Authors:  Yu Pei; Robert W Maitta
Journal:  Heliyon       Date:  2019-10-18

10.  Regulatory impairment in untreated Parkinson's disease is not restricted to Tregs: other regulatory populations are also involved.

Authors:  Diana D Álvarez-Luquín; Asiel Arce-Sillas; Jaquelín Leyva-Hernández; Edgar Sevilla-Reyes; Marie Catherine Boll; Esteban Montes-Moratilla; Viridiana Vivas-Almazán; Citzielli Pérez-Correa; Ulises Rodríguez-Ortiz; Raquel Espinoza-Cárdenas; Gladis Fragoso; Edda Sciutto; Laura Adalid-Peralta
Journal:  J Neuroinflammation       Date:  2019-11-11       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.